Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,849 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04007770 | Acupuncture Pilot Study for Cancer-related Cognitive Function | active not recruiting | Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04354246 | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | completed | Phase 1 | 94 | Compugen LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05338307 |
| Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention(BHB-CRC) |
| active not recruiting |
| N/A |
| 20 |
| Abramson Cancer Center at Penn MedicineOTHER |
| 1 |
| Aug 12, 2026 |
| clinicaltrials |
| NCT07079462 | Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis | active not recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07125729 | Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients | recruiting | N/A | 150 | City of Hope Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07136077 | A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.(DUNP19) | not yet recruiting | Phase 1 | 16 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07277322 | Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases | recruiting | Phase 1 / Phase 2 | 24 | Dan FengOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07759960 | Underwater Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Small Rectal Neuroendocrine Tumors | recruiting | N/A | 174 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07761169 | Randomized Controlled Trial of the SurgDiff Model for Predicting Surgical Difficulty to Help Choose Approach in Mid-Low Rectal Cancer | not yet recruiting | N/A | 68 | Peking Union Medical College HospitalOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT00648635 | Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations | active not recruiting | — | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04068610 | COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | active not recruiting | Phase 1 / Phase 2 | 61 | MedImmune LLCINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06323421 | Targeting Chronic Stress for Reducing Risk Factors for Colorectal Cancer(MindCRC) | completed | N/A | 24 | University of Illinois at ChicagoOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06593678 | Telerehabilitation in Cancer Patients: Optimization of Prehabilitation and Rehabilitation Following Colorectal Resection(CCR) | completed | N/A | 80 | Instituto de Investigación Sanitaria AragónOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06806046 | Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors | active not recruiting | Phase 1 | 12 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07071714 | A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer | active not recruiting | Phase 2 | 103 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04525989 | Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT)(PRORECT) | recruiting | N/A | 254 | Alexander ValdmanOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05534087 | Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)(CLAUDIA) | recruiting | Phase 3 | 236 | Seoul National University HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05694559 | Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics | recruiting | N/A | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06269978 | Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer | active not recruiting | Phase 1 | 9 | Arjun MittraOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06501053 | Contact Radiotherapy for Rectal Cancer(CORRECT) | recruiting | N/A | 110 | Alexander ValdmanOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06577194 | Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01) | active not recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07550088 | BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases | recruiting | Phase 2 | 17 | Darren Sigal, MDOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07722494 | IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer | recruiting | Phase 3 | 550 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07754513 | Circulating Tumor Extracellular Vesicles for Non-Invasive Monitoring of Metastatic Colorectal Cancer(EVA26) | not yet recruiting | — | 290 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Aug 10, 2026 | clinicaltrials |
| NCT07755124 | Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial | not yet recruiting | Phase 1 / Phase 2 | 140 | West China HospitalOTHER | 0 | Aug 10, 2026 | clinicaltrials |
| NCT00265850 | Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 2,334 | Alliance for Clinical Trials in OncologyOTHER | 2 | Aug 7, 2026 | clinicaltrials |
| NCT03844620 | Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06751329 | A Study of DM002 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT06880055 | Shield Post-Approval Study Protocol(SOLAR) | recruiting | — | 3,375 | Guardant Health, Inc.INDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07162714 | SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer(STAR) | recruiting | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT02965703 | Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma | active not recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04104139 | TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer | completed | Phase 1 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05524012 | Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer(PRIMO) | active not recruiting | — | 40 | Jena University HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 165 | Genentech, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | recruiting | Phase 1 | 30 | University of PennsylvaniaOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07744139 | Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis(RaP-DMac-LiMe) | not yet recruiting | — | 210 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07750041 | A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 260 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT01394939 | Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 52 | Jennerex BiotherapeuticsINDUSTRY | 3 | Aug 5, 2026 | clinicaltrials |
| NCT02970513 | Psychological Evaluation According Colonic Colonization by Escherichia Coli of Patients After Colorectal Surgery(MicrobioPSY) | completed | N/A | 12 | University Hospital, Clermont-FerrandOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04999761 | AB122 Platform Study | recruiting | Phase 1 | 917 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05826743 | Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy(COLO-BT) | recruiting | N/A | 256 | JSR Medical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06714292 | Fluorescent Approach for Refined Endoscopic Marking With Clip Localization and Identification Procedure(FLARECLIP) | completed | Phase 2 | 110 | Seoul National University HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability(DEFEND) | recruiting | N/A | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07209215 | ctDNA-Informed Management of Early-Stage Rectal Cancer(ULTIMATE) | not yet recruiting | Phase 2 | 200 | University of California, DavisOTHER | 1 | Aug 5, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 12, 2026source: clinicaltrials